Efficacy of some combination regimens of oral hypoglycaemic agents in type 2 diabetes mellitus patients

Research output: Contribution to journalArticle

Abstract

Purpose: To examine the efficacy of selected oral hypoglycaemic agent (OHA) regimens in a small group of patients receiving such treatment. Methods: This was a retrospective, observational study that involved patients who had been diagnosed with type 2 diabetes mellitus and undergoing routine follow-up at a teaching hospital. By reviewing patients’ medical records, changes in fasting blood glucose (FPG) and glycated haemoglobin (HbA1c) levels induced by several OHA cobmination regimens were documented. Target FPG and HbA1c were defined as 4.4 - 6.1 mmol/L and 6.5 %, respectively. Results: Based on the medical records of 156 patients reviewed, the combination of metformin and gliclazide was the most commonly prescribed regimen (63.46 %). The use of gliclazide + rosiglitazone + acarbose produced the greatest reduction in FPG and HbA1c (-4.80 mmol/L and - 4.20 %, respectively), but the number of patients receiving this combination was too small to allow definitive conclusions to be made. More patients in the triple OHA group were able to achieve the desired glycaemic control than those in the dual OHA group (FPG, 44.44 % versus 41.18 %; HbA1c, 52.94 % versus 47.06 %), highlighting the important benefits conferred by the use of multiple OHAs. Conclusion: The efficacy of various OHA combinations varies, and adding a third drug to a dual-agent regimen further reduces FPG and HbA1c levels. Though gliclazide + rosiglitazone + acarbose produces the greatest reduction in FPG and HbA1c levels, larger studies are required to confirm these findings.

Original languageEnglish
Pages (from-to)1279-1284
Number of pages6
JournalTropical Journal of Pharmaceutical Research
Volume14
Issue number7
DOIs
Publication statusPublished - 1 Jul 2015

Fingerprint

Hypoglycemic Agents
Type 2 Diabetes Mellitus
rosiglitazone
Gliclazide
Acarbose
Medical Records
Metformin
Glycosylated Hemoglobin A
Teaching Hospitals
Observational Studies
Blood Glucose
Fasting
Retrospective Studies
Pharmaceutical Preparations

Keywords

  • Acarbose
  • Combination therapy
  • Fasting plasma glucose (FPG)
  • Gliclazide
  • Glycated haemoglobin (HbA1c)
  • Oral hypoglycaemic agents
  • Rosiglitazone
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

@article{324f7aaffee54f38ae102f592a51b131,
title = "Efficacy of some combination regimens of oral hypoglycaemic agents in type 2 diabetes mellitus patients",
abstract = "Purpose: To examine the efficacy of selected oral hypoglycaemic agent (OHA) regimens in a small group of patients receiving such treatment. Methods: This was a retrospective, observational study that involved patients who had been diagnosed with type 2 diabetes mellitus and undergoing routine follow-up at a teaching hospital. By reviewing patients’ medical records, changes in fasting blood glucose (FPG) and glycated haemoglobin (HbA1c) levels induced by several OHA cobmination regimens were documented. Target FPG and HbA1c were defined as 4.4 - 6.1 mmol/L and 6.5 {\%}, respectively. Results: Based on the medical records of 156 patients reviewed, the combination of metformin and gliclazide was the most commonly prescribed regimen (63.46 {\%}). The use of gliclazide + rosiglitazone + acarbose produced the greatest reduction in FPG and HbA1c (-4.80 mmol/L and - 4.20 {\%}, respectively), but the number of patients receiving this combination was too small to allow definitive conclusions to be made. More patients in the triple OHA group were able to achieve the desired glycaemic control than those in the dual OHA group (FPG, 44.44 {\%} versus 41.18 {\%}; HbA1c, 52.94 {\%} versus 47.06 {\%}), highlighting the important benefits conferred by the use of multiple OHAs. Conclusion: The efficacy of various OHA combinations varies, and adding a third drug to a dual-agent regimen further reduces FPG and HbA1c levels. Though gliclazide + rosiglitazone + acarbose produces the greatest reduction in FPG and HbA1c levels, larger studies are required to confirm these findings.",
keywords = "Acarbose, Combination therapy, Fasting plasma glucose (FPG), Gliclazide, Glycated haemoglobin (HbA1c), Oral hypoglycaemic agents, Rosiglitazone, Type 2 diabetes mellitus",
author = "Endang, {Kumolosasi Msi} and Yan, {Gan Boon} and Chua, {Eng Wee}",
year = "2015",
month = "7",
day = "1",
doi = "10.4314/tjpr.v14i7.22",
language = "English",
volume = "14",
pages = "1279--1284",
journal = "Tropical Journal of Pharmaceutical Research",
issn = "1596-5996",
publisher = "Pharmacotherapy Group",
number = "7",

}

TY - JOUR

T1 - Efficacy of some combination regimens of oral hypoglycaemic agents in type 2 diabetes mellitus patients

AU - Endang, Kumolosasi Msi

AU - Yan, Gan Boon

AU - Chua, Eng Wee

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Purpose: To examine the efficacy of selected oral hypoglycaemic agent (OHA) regimens in a small group of patients receiving such treatment. Methods: This was a retrospective, observational study that involved patients who had been diagnosed with type 2 diabetes mellitus and undergoing routine follow-up at a teaching hospital. By reviewing patients’ medical records, changes in fasting blood glucose (FPG) and glycated haemoglobin (HbA1c) levels induced by several OHA cobmination regimens were documented. Target FPG and HbA1c were defined as 4.4 - 6.1 mmol/L and 6.5 %, respectively. Results: Based on the medical records of 156 patients reviewed, the combination of metformin and gliclazide was the most commonly prescribed regimen (63.46 %). The use of gliclazide + rosiglitazone + acarbose produced the greatest reduction in FPG and HbA1c (-4.80 mmol/L and - 4.20 %, respectively), but the number of patients receiving this combination was too small to allow definitive conclusions to be made. More patients in the triple OHA group were able to achieve the desired glycaemic control than those in the dual OHA group (FPG, 44.44 % versus 41.18 %; HbA1c, 52.94 % versus 47.06 %), highlighting the important benefits conferred by the use of multiple OHAs. Conclusion: The efficacy of various OHA combinations varies, and adding a third drug to a dual-agent regimen further reduces FPG and HbA1c levels. Though gliclazide + rosiglitazone + acarbose produces the greatest reduction in FPG and HbA1c levels, larger studies are required to confirm these findings.

AB - Purpose: To examine the efficacy of selected oral hypoglycaemic agent (OHA) regimens in a small group of patients receiving such treatment. Methods: This was a retrospective, observational study that involved patients who had been diagnosed with type 2 diabetes mellitus and undergoing routine follow-up at a teaching hospital. By reviewing patients’ medical records, changes in fasting blood glucose (FPG) and glycated haemoglobin (HbA1c) levels induced by several OHA cobmination regimens were documented. Target FPG and HbA1c were defined as 4.4 - 6.1 mmol/L and 6.5 %, respectively. Results: Based on the medical records of 156 patients reviewed, the combination of metformin and gliclazide was the most commonly prescribed regimen (63.46 %). The use of gliclazide + rosiglitazone + acarbose produced the greatest reduction in FPG and HbA1c (-4.80 mmol/L and - 4.20 %, respectively), but the number of patients receiving this combination was too small to allow definitive conclusions to be made. More patients in the triple OHA group were able to achieve the desired glycaemic control than those in the dual OHA group (FPG, 44.44 % versus 41.18 %; HbA1c, 52.94 % versus 47.06 %), highlighting the important benefits conferred by the use of multiple OHAs. Conclusion: The efficacy of various OHA combinations varies, and adding a third drug to a dual-agent regimen further reduces FPG and HbA1c levels. Though gliclazide + rosiglitazone + acarbose produces the greatest reduction in FPG and HbA1c levels, larger studies are required to confirm these findings.

KW - Acarbose

KW - Combination therapy

KW - Fasting plasma glucose (FPG)

KW - Gliclazide

KW - Glycated haemoglobin (HbA1c)

KW - Oral hypoglycaemic agents

KW - Rosiglitazone

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84938299640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938299640&partnerID=8YFLogxK

U2 - 10.4314/tjpr.v14i7.22

DO - 10.4314/tjpr.v14i7.22

M3 - Article

VL - 14

SP - 1279

EP - 1284

JO - Tropical Journal of Pharmaceutical Research

JF - Tropical Journal of Pharmaceutical Research

SN - 1596-5996

IS - 7

ER -